CO5650245A2 - DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT - Google Patents

DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT

Info

Publication number
CO5650245A2
CO5650245A2 CO05130971A CO05130971A CO5650245A2 CO 5650245 A2 CO5650245 A2 CO 5650245A2 CO 05130971 A CO05130971 A CO 05130971A CO 05130971 A CO05130971 A CO 05130971A CO 5650245 A2 CO5650245 A2 CO 5650245A2
Authority
CO
Colombia
Prior art keywords
agent
inflammatory agent
organ
inflammatory
agents
Prior art date
Application number
CO05130971A
Other languages
Spanish (es)
Inventor
Nancy Britten
Niki A Waldron
Jeffrey L Watts
John W Hallberg
Ii John William Burns
Original Assignee
Pharmacia And Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia And Upjohn Company Llc filed Critical Pharmacia And Upjohn Company Llc
Publication of CO5650245A2 publication Critical patent/CO5650245A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Un procedimiento para el tratamiento y/o prevención de una afección inflamatoria en un órgano que contiene fluidos que tiene un orificio exterior natural, comprendiendo el procedimiento administrar una composición farmacéutica que comprende un agente anti-inflamatorio al órgano mediante el orificio exterior, comprendiendo además dicha composición un vehículo que comprende (a) un aceite anfipático que es dispersable en agua e insoluble en etanol (b) cera microcristalina, y (c) un vehículo no acuoso farmacéuticamente aceptable; y administrar en terapia de combinación con dicho agente anti-inflamatorio un segundo agente seleccionado entre el grupo compuesto por agentes antibacterianos, analgésicos, antipiréticos, anestésicos, bloqueantes de los canales de sodio, agentes anti-neoplásicos y agentes antiedémicos, donde el segundo agente se administra mediante una vía distinta de la vía de administración del agente anti-inflamatorio.2.- El procedimiento de la reivindicación 1 en el que el órgano que contiene fluidos es una ubre de un animal que produce leche y donde la composición se administra por infusión intramamaria.3.- El procedimiento de la reivindicación 2, en el que la afección inflamatoria se asocia con mastitis.1. A procedure for the treatment and / or prevention of an inflammatory condition in an organ that contains fluids having a natural outer opening, the method comprising administering a pharmaceutical composition comprising an anti-inflammatory agent to the organ through the outer opening, said composition further comprising a vehicle comprising (a) an amphipathic oil that is dispersible in water and insoluble in ethanol (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous vehicle; and administering in combination therapy with said anti-inflammatory agent a second agent selected from the group consisting of antibacterial, analgesic, antipyretic, anesthetic agents, sodium channel blockers, anti-neoplastic agents and anti-anemic agents, where the second agent is administered by a route other than the route of administration of the anti-inflammatory agent. 2. The method of claim 1 wherein the organ containing fluids is an udder of an animal that produces milk and where the composition is administered by infusion. intramammary. 3. The method of claim 2, wherein the inflammatory condition is associated with mastitis.

CO05130971A 2003-07-31 2005-12-29 DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT CO5650245A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
CO5650245A2 true CO5650245A2 (en) 2006-06-30

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05130971A CO5650245A2 (en) 2003-07-31 2005-12-29 DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT

Country Status (14)

Country Link
EP (1) EP1651210A1 (en)
JP (1) JP2007500691A (en)
KR (1) KR100780983B1 (en)
CN (1) CN1829510A (en)
AU (1) AU2004258745A1 (en)
BR (1) BRPI0412581A (en)
CA (1) CA2533101A1 (en)
CO (1) CO5650245A2 (en)
IL (1) IL172735A0 (en)
MX (1) MXPA06001288A (en)
NO (1) NO20060982L (en)
RU (1) RU2319508C2 (en)
WO (1) WO2005009436A1 (en)
ZA (1) ZA200600096B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (en) 2006-12-20 2008-10-17 Schering Plough Ltd PHARMACEUTICAL COMPOSITIONS OF FLUNIXIN
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
UA111147C2 (en) * 2009-11-11 2016-04-11 Байєр Б.В. METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF EXTERNAL OTITIS
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
ES2391721T3 (en) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Transparent aqueous solutions of fluocinolone acetonide for the treatment of ear swelling
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
RU2486905C1 (en) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Method of treating mastitis in animals
CN102784161A (en) * 2012-08-01 2012-11-21 张吉川 Specific ear drops for treating acute/chronic tympanitis
EP2925367B1 (en) * 2013-01-14 2019-08-14 InFirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treatment of subclinical mastitis in cows
PE20181153A1 (en) 2015-08-05 2018-07-17 Childrens Medical Center COMPOSITIONS WITH PRIZE POTENTIALS FOR THE SUPPLY OF DRUGS
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (en) * 2015-08-27 2017-05-23 심민보 Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus comprising platelet-rich plasma and method using the same
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
RU2749857C1 (en) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Method for combatting otitis media and otitis externa
RU2751697C1 (en) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Remedy for treatment of otitis of external auditory canal in dogs
KR102461699B1 (en) * 2021-05-21 2022-11-03 현대약품 주식회사 Gargle solution with improved stability comprising benzidamine hydrochloride
WO2023101421A1 (en) * 2021-12-03 2023-06-08 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus
KR20230084419A (en) * 2021-12-03 2023-06-13 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
MX9702699A (en) * 1994-10-26 1997-06-28 Novartis Ag Pharmaceutical compositions.
DE69620136T2 (en) * 1995-06-06 2002-08-01 Bayer Ag ANTIBACTERIAL PREPARATIONS FOR THE EARS WITHOUT IRRITATING, SENSITIZING AND OTOTOXIC EFFECTS
DZ2479A1 (en) * 1997-05-05 2003-02-01 Pfizer Anti-inflammatory selective co-2 inhibitor compounds and pharmaceutical compositions containing them.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
AU2001268512A1 (en) * 2000-06-16 2002-01-02 Hercules Incorporated Chemically-modified peptides, compositions, and methods of production and use
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20020068065A1 (en) * 2000-09-12 2002-06-06 Ondrej Hendl Pharmaceutical composition having specific water activity
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
WO2005009436A1 (en) 2005-02-03
CA2533101A1 (en) 2005-02-03
EP1651210A1 (en) 2006-05-03
BRPI0412581A (en) 2006-09-19
IL172735A0 (en) 2006-04-10
MXPA06001288A (en) 2006-04-11
WO2005009436A8 (en) 2005-05-06
RU2319508C2 (en) 2008-03-20
AU2004258745A1 (en) 2005-02-03
KR100780983B1 (en) 2007-11-30
KR20060031873A (en) 2006-04-13
NO20060982L (en) 2006-05-02
CN1829510A (en) 2006-09-06
ZA200600096B (en) 2007-02-28
RU2006101628A (en) 2006-08-27
JP2007500691A (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CO5650245A2 (en) DISPERSABLE FORMULATIONS OF AN ANTI-INFLAMMATORY AGENT
UY28236A1 (en) DISPERSABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MASTITIS AND OTIC DISORDERS.
CO5611169A2 (en) DISPERSABLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT
AR042537A1 (en) AVAILABLE PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBACTERIALS FOR MILK PRODUCING ANIMALS
US5260073A (en) Use of phenylpropanolamine as a mucus secretogogue in the upper airways
ES2213139T5 (en) TREATMENT OF NON-INFLAMMATORY INTESTINAL DISORDERS.
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
DE69906518D1 (en) DRUG DISPENSING SYSTEM CONTAINS A SOLID, SOLID, DRY-BASED BASIS
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
ES2236180T3 (en) ANTIALERGIC OPHTHALMIC COMPOSITIONS SUITABLE FOR USE WITH CONTACT LENSES.
AR002049A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS THAT HAVE LOW SOLUBILITY IN WATER AND THE PROCEDURE TO PREPARE IT
JP2007536257A (en) Soft gel encapsulated pharmaceutical composition containing concentrated active ingredients
EP0530311A1 (en) The use of phenylpropanolamine as a mucus secretagogue in the upper airways
AR030630A1 (en) PHARMACEUTICAL COMPOSITIONS
AR041069A1 (en) ORAL LIQUID TOLTERODINE COMPOSITION
PE20010568A1 (en) ORAL CONTROLLED RELEASE FORMULATIONS
AR022338A1 (en) A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT.
DE60331920D1 (en) ORAL PHARMACEUTICAL COMPOSITION FOR SOAP CAPSULES WITH VINORELBIN AND TREATMENT PROCEDURES
AR022348A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYMPTOMS OF LOWER URINARY TRACT
RU2002110952A (en) Cream "Bramisil" antifungal action
JP2023120462A (en) Pharmaceutical composition
JP6154718B2 (en) Lower urinary tract disease treatment
ES2172818T3 (en) USE OF LH-RH ANTAGONISTS AS A DIAGNOSTIC AGENT.
JP5217530B2 (en) Suppository
PE20040204A1 (en) ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

Legal Events

Date Code Title Description
FC Application refused